دورية أكاديمية
أعرض في EDS

Glucagon-like peptide 1 (GLP-1) can reverse AMP-activated protein kinase (AMPK) and S6 kinase (P70S6K) activities induced by fluctuations in glucose levels in hypothalamic areas involved in feeding behaviour.

التفاصيل البيبلوغرافية
العنوان: Glucagon-like peptide 1 (GLP-1) can reverse AMP-activated protein kinase (AMPK) and S6 kinase (P70S6K) activities induced by fluctuations in glucose levels in hypothalamic areas involved in feeding behaviour.
المؤلفون: Hurtado-Carneiro V; Department of Biochemistry and Molecular Biology, Faculty of Medicine, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Complutense University, Ciudad Universitaria, sn, 28040 Madrid, Spain., Sanz C, Roncero I, Vazquez P, Blazquez E, Alvarez E
المصدر: Molecular neurobiology [Mol Neurobiol] 2012 Apr; Vol. 45 (2), pp. 348-61. Date of Electronic Publication: 2012 Feb 05.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Humana Press Country of Publication: United States NLM ID: 8900963 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-1182 (Electronic) Linking ISSN: 08937648 NLM ISO Abbreviation: Mol Neurobiol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Clifton, NJ : Humana Press, c1987-
مواضيع طبية MeSH: AMP-Activated Protein Kinases/*metabolism , Feeding Behavior/*physiology , Glucagon-Like Peptide 1/*physiology , Glucose/*metabolism , Hypothalamus/*metabolism , Ribosomal Protein S6 Kinases/*metabolism, AMP-Activated Protein Kinases/antagonists & inhibitors ; AMP-Activated Protein Kinases/genetics ; Animals ; Feeding Behavior/drug effects ; Glucagon-Like Peptide 1/genetics ; Glucose/biosynthesis ; Hypothalamic Area, Lateral/cytology ; Hypothalamic Area, Lateral/enzymology ; Hypothalamic Area, Lateral/metabolism ; Hypothalamus/cytology ; Hypothalamus/enzymology ; Male ; Organ Culture Techniques ; Rats ; Rats, Wistar ; Rats, Zucker ; Ribosomal Protein S6 Kinases/antagonists & inhibitors ; Ribosomal Protein S6 Kinases/genetics ; Ventromedial Hypothalamic Nucleus/cytology ; Ventromedial Hypothalamic Nucleus/enzymology ; Ventromedial Hypothalamic Nucleus/metabolism
مستخلص: The anorexigenic peptide, glucagon-like peptide-1 (GLP-1), reduces glucose metabolism in the human hypothalamus and brain stem. The brain activity of metabolic sensors such as AMP-activated protein kinase (AMPK) responds to changes in glucose levels. The mammalian target of rapamycin (mTOR) and its downstream target, p70S6 kinase (p70S6K), integrate nutrient and hormonal signals. The hypothalamic mTOR/p70S6K pathway has been implicated in the control of feeding and the regulation of energy balances. Therefore, we investigated the coordinated effects of glucose and GLP-1 on the expression and activity of AMPK and p70S6K in the areas involved in the control of feeding. The effect of GLP-1 on the expression and activities of AMPK and p70S6K was studied in hypothalamic slice explants exposed to low- and high-glucose concentrations by quantitative real-time RT-PCR and by the quantification of active-phosphorylated protein levels by immunoblot. In vivo, the effects of exendin-4 on hypothalamic AMPK and p70S6K activation were analysed in male obese Zucker and lean controls 1 h after exendin-4 injection to rats fasted for 48 h or after re-feeding for 2-4 h. High-glucose levels decreased the expression of Ampk in the lateral hypothalamus and treatment with GLP-1 reversed this effect. GLP-1 treatment inhibited the activities of AMPK and p70S6K when the activation of these protein kinases was maximum in both the ventromedial and lateral hypothalamic areas. Furthermore, in vivo s.c. administration of exendin-4 modulated AMPK and p70S6K activities in those areas, in both fasted and re-fed obese Zucker and lean control rats.
References: Metabolism. 2000 Jun;49(6):709-17. (PMID: 10877194)
J Neurochem. 2000 May;74(5):1848-57. (PMID: 10800927)
Metabolism. 2008 Jan;57(1):40-8. (PMID: 18078857)
Diabetes. 2003 Feb;52(2):227-31. (PMID: 12540590)
Diabetes. 2006 Jun;55(6):1755-60. (PMID: 16731839)
Nature. 2004 Apr 1;428(6982):569-74. (PMID: 15058305)
J Clin Invest. 2006 Jul;116(7):1776-83. (PMID: 16823475)
Cell Metab. 2007 Jul;6(1):55-68. (PMID: 17618856)
Transplant Proc. 2009 Jul-Aug;41(6 Suppl):S31-8. (PMID: 19651294)
J Biol Chem. 2003 Aug 1;278(31):28434-42. (PMID: 12764152)
Lancet. 2009 Jul 4;374(9683):39-47. (PMID: 19515413)
J Biol Chem. 2004 Mar 26;279(13):12005-8. (PMID: 14742438)
PLoS One. 2011;6(9):e24909. (PMID: 21966382)
J Neurochem. 2002 Jan;80(1):45-53. (PMID: 11796742)
J Clin Invest. 2008 Aug;118(8):2959-68. (PMID: 18618016)
J Neurochem. 2004 Mar;88(5):1203-10. (PMID: 15009676)
Nature. 1998 May 7;393(6680):72-6. (PMID: 9590691)
Cell Metab. 2011 Mar 2;13(3):320-30. (PMID: 21356521)
J Neurochem. 1996 Nov;67(5):1982-91. (PMID: 8863504)
J Neurochem. 2005 Feb;92(4):798-806. (PMID: 15686481)
Neuron. 1990 Jul;5(1):1-10. (PMID: 2196069)
Diabetes Obes Metab. 2006 Jul;8(4):436-47. (PMID: 16776751)
Nature. 1996 Jan 4;379(6560):69-72. (PMID: 8538742)
Annu Rev Biochem. 1998;67:821-55. (PMID: 9759505)
J Endocrinol. 2007 May;193(2):259-67. (PMID: 17470517)
J Neurochem. 1996 Mar;66(3):920-7. (PMID: 8769850)
Clin Ther. 2009 Nov;31(11):2472-88. (PMID: 20109994)
J Neurochem. 2008 May;105(3):833-41. (PMID: 18088373)
Diabetes. 2008 Feb;57(2):444-50. (PMID: 17977955)
Nature. 2001 Oct 25;413(6858):794-5. (PMID: 11677594)
Front Biosci (Landmark Ed). 2009 Jan 01;14:19-44. (PMID: 19273052)
J Neurosci. 1994 Aug;14(8):5068-76. (PMID: 8046468)
Science. 2006 May 12;312(5775):927-30. (PMID: 16690869)
Endocrinology. 2005 Jan;146(1):3-10. (PMID: 15375032)
Endocrinology. 2001 Aug;142(8):3457-63. (PMID: 11459791)
J Mol Endocrinol. 2010 Feb;44(2):87-97. (PMID: 19625456)
J Clin Invest. 2007 Aug;117(8):2325-36. (PMID: 17671657)
Exp Physiol. 2007 Mar;92(2):311-9. (PMID: 17158178)
Diabetes Obes Metab. 2010 Apr;12(4):267-87. (PMID: 20380648)
Peptides. 2006 Jul;27(7):1607-15. (PMID: 16580091)
Nat Rev Mol Cell Biol. 2007 Oct;8(10):774-85. (PMID: 17712357)
Diabetologia. 2007 Jan;50(1):168-77. (PMID: 17093945)
Endocr J. 2008 Oct;55(5):867-74. (PMID: 18506089)
FASEB J. 2010 Dec;24(12):5080-91. (PMID: 20724523)
Mol Neurobiol. 1998 Oct;18(2):157-73. (PMID: 10065878)
J Biol Chem. 2004 Jan 9;279(2):1070-9. (PMID: 14573616)
J Clin Invest. 2003 Jan;111(1):91-8. (PMID: 12511592)
Biochem J. 2003 Oct 1;375(Pt 1):1-16. (PMID: 12839490)
Nat Med. 2004 Jul;10(7):727-33. (PMID: 15195087)
J Physiol. 2006 Jul 1;574(Pt 1):7-15. (PMID: 16644800)
المشرفين على المادة: 89750-14-1 (Glucagon-Like Peptide 1)
EC 2.7.11.1 (Ribosomal Protein S6 Kinases)
EC 2.7.11.31 (AMP-Activated Protein Kinases)
IY9XDZ35W2 (Glucose)
تواريخ الأحداث: Date Created: 20120208 Date Completed: 20121204 Latest Revision: 20211021
رمز التحديث: 20221213
DOI: 10.1007/s12035-012-8239-z
PMID: 22311299
قاعدة البيانات: MEDLINE
الوصف
تدمد:1559-1182
DOI:10.1007/s12035-012-8239-z